Amylyx Pharmaceuticals Q4 & FY2025 Financial Results: Key Highlights for Investors
Amylyx Pharmaceuticals Reports Q4 & Full Year 2025 Financial Results
Executive Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) has released its financial and business results for the fourth quarter and full year ended December 31, 2025. The report contains significant developments in its clinical programs—most notably, its pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH), as well as updates on other pipeline assets and a detailed breakdown of financial performance.
Key Business Developments
- LUCIDITY Phase 3 Trial for Avexitide in PBH: Recruitment is now complete. Amylyx expects to randomize and dose the last eligible participants in Q1 2026, with topline data anticipated in Q3 2026. If trial results are positive and the drug is approved, commercialization could occur in 2027.
- Cash Runway: Amylyx reports sufficient cash and equivalents to fund operations through potential avexitide commercialization and into 2028. This robust financial position provides stability for ongoing and future development activities.
- Pipeline Progress:
- AMX0318: Announced as a novel GLP-1 receptor agonist for long-acting administration in PBH and other rare diseases. Demonstrated strong preclinical and chemical properties, with IND-enabling studies underway and IND filing targeted for 2027.
- AMX0114: Early safety and tolerability data from Cohort 1 of the Phase 1 LUMINA trial presented; AMX0114 (an antisense oligonucleotide targeting calpain-2 for ALS) received FDA Fast Track Designation. Cohort 1 (n=12) showed no treatment-related serious adverse events.
- Regulatory Milestones: Amylyx is actively preparing for a regulatory submission and building commercial infrastructure in anticipation of avexitide commercialization.
Financial Performance Highlights
- R&D Expenses: \$21.2 million for Q4 2025 (down from \$22.9 million in Q4 2024); \$90.4 million for FY2025 (down from \$104.1 million in FY2024). The decrease was due to reduced spending on AMX0035 (ALS and PSP), offset by increased avexitide development costs.
- SG&A Expenses: \$15.4 million for Q4 2025 (down from \$17.1 million in Q4 2024); \$62.9 million for FY2025 (down from \$114.3 million in FY2024). The decline was primarily due to reduced consulting and professional services.
- Net Loss: \$33.0 million for Q4 2025 (\$0.30 per share), compared to \$37.5 million (\$0.55 per share) in Q4 2024. FY2025 net loss was \$144.7 million (\$1.53 per share), compared to \$301.7 million (\$4.43 per share) in FY2024.
- Cash Position: Cash, cash equivalents, and short-term investments totaled \$317.0 million at December 31, 2025, down from \$344.0 million at September 30, 2025.
- Balance Sheet: Total assets of \$332.6 million and total liabilities of \$27.4 million at December 31, 2025. Stockholders’ equity increased to \$305.3 million, up from \$164.8 million at the end of 2024.
Clinical Pipeline and Upcoming Catalysts
- Avexitide in PBH:
- First-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation.
- LUCIDITY trial (75 participants, multicenter, randomized, double-blind, placebo-controlled) evaluates avexitide’s efficacy and safety, with primary endpoint being reduction in Level 2 and Level 3 hypoglycemic events at Week 16.
- Participants completing the double-blind phase may enter a 32-week open-label extension.
- No approved therapies currently exist for PBH; market opportunity estimated at ~160,000 people in the U.S.
- AMX0114 for ALS:
- Cohort 2 enrollment in Phase 1 LUMINA trial expected in March 2026, with biomarker data from Cohort 1 expected in 1H 2026.
- Trial evaluates safety, tolerability, PK/PD, and novel ALS biomarkers including neurofilament light chain (NfL).
- AMX0318:
- IND-enabling studies ongoing, with IND filing targeted for 2027.
- Extensive preclinical evaluation completed.
Shareholder Considerations & Potential Price-Sensitive Items
- Pivotal Phase 3 Clinical Results in Q3 2026: Topline data from the LUCIDITY trial for avexitide will be a major catalyst. Positive results could significantly uplift share value due to the commercial potential in a currently untapped market.
- Commercial Launch Timeline: If approved, avexitide could launch in 2027. Amylyx is actively preparing regulatory and commercial infrastructure, positioning the company for revenue growth.
- Financial Stability: Cash runway into 2028 reduces risk of near-term dilution or funding concerns.
- Pipeline Expansion: New candidate AMX0318 and progress in ALS program with AMX0114 give Amylyx additional shots on goal, diversifying its future value drivers.
- Reduced Operating Losses: The sharp decrease in net losses compared to 2024 and the increase in stockholders’ equity show improved financial management and operational discipline.
- Regulatory and Clinical Risks: As with any biotech, regulatory outcomes and clinical data readouts remain key risk factors. Investors should monitor upcoming milestones closely.
Corporate Information
Amylyx intends to use its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD. Investors are encouraged to monitor the company’s website and investor relations portal for updates, including press releases, SEC filings, and conference call webcasts.
Contact Information
Disclaimer
This article contains forward-looking statements based on management’s current expectations and is subject to risks and uncertainties, including clinical trial outcomes, regulatory approvals, and financial performance. Actual results may differ materially. Investors should review Amylyx’s SEC filings and consult with financial advisors before making investment decisions. This article does not constitute investment advice.
View Amylyx Pharmaceuticals, Inc. Historical chart here
